Adma Biologics (ADMA) Payables (2011 - 2026)
Adma Biologics' (ADMA) quarterly Payables came in at $22.5 million in Q4 2025, up 11.38% YoY from $20.2 million in Q4 2024, and down 6.25% on a QoQ basis from $24.0 million in Q3 2025.
Adma Biologics (ADMA) Payables (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Payables data on file, last reported at $22.5 million in Q4 2025.
- Quarterly Payables rose 11.38% year-over-year to $22.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.5 million (up 11.38% YoY) and the FY2025 annual result came in at $22.5 million, up 11.38% from the prior year.
- Payables slipped to $22.5 million in Q4 2025, from $24.0 million in the prior quarter.
- In the past five years, Payables ranged from a high of $29.8 million in Q2 2025 to a low of $6.2 million in Q2 2021.
- A 5-year average of $16.4 million and a median of $14.9 million in 2023 frame the typical range for Payables.
- Annual changes were most pronounced in 2021 — Payables soared 116.58% — and 2023, when it plunged 56.93%.
- Tracing ADMA's Payables over 5 years: stood at $12.4 million in 2021, then increased by 6.43% to $13.2 million in 2022, then increased by 18.38% to $15.7 million in 2023, then gained by 29.11% to $20.2 million in 2024, then increased by 11.38% to $22.5 million in 2025.
- The last three Payables figures came in at $22.5 million (Q4 2025), $24.0 million (Q3 2025), and $29.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 31.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.72 Mn |
| Dec 31, 2025 | 22.52 Mn |
| Sep 30, 2025 | 24.02 Mn |
| Jun 30, 2025 | 29.77 Mn |
| Mar 31, 2025 | 20.61 Mn |
| Dec 31, 2024 | 20.22 Mn |
| Sep 30, 2024 | 16.02 Mn |
| Jun 30, 2024 | 14.18 Mn |
| Mar 31, 2024 | 17.19 Mn |
| Dec 31, 2023 | 15.66 Mn |
| Sep 30, 2023 | 10.85 Mn |
| Jun 30, 2023 | 12.08 Mn |
| Mar 31, 2023 | 12.96 Mn |
| Dec 31, 2022 | 13.23 Mn |
| Sep 30, 2022 | 25.20 Mn |
| Jun 30, 2022 | 11.39 Mn |
| Mar 31, 2022 | 14.12 Mn |
| Dec 31, 2021 | 12.43 Mn |
| Sep 30, 2021 | 17.28 Mn |
| Jun 30, 2021 | 6.17 Mn |